Solid Biosciences Receives Rare Pediatric Disease Designation for Duchenne

  SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. –

– Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 –

https://www.globenewswire.com/news-release/2024/04/01/2855112/0/en/Solid-Biosciences-Receives-Rare-Pediatric-Disease-Designation-from-the-FDA-for-Duchenne-Muscular-Dystrophy-Gene-Therapy-Candidate-SGT-003.html